simurosertib   Click here for help

GtoPdb Ligand ID: 10317

Synonyms: example 108 [US9655900B2] | TAK-931 | TAK931
PDB Ligand
Compound class: Synthetic organic
Comment: Simurosertib (TAK-931) is an oral Cdc7 (cell division cycle 7-related protein kinase) inhibitor that is being developed by Millennium Pharmaceuticals/Takeda for potential antineoplastic activity in CDC7-overexpressing tumour cells [3]. Cdc7 is a serine/threonine kinase and cell division cycle protein. Simurosertib sensitizes tumour cells to DNA-damaging chemotherapies by functioning to disrupt the cells' ability to recover from DNA damage [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 2
Topological polar surface area 105.91
Molecular weight 341.13
XLogP 1.96
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1[nH]ncc1c1sc2c(c1)nc([nH]c2=O)C1CC2CCN1CC2
Isomeric SMILES Cc1[nH]ncc1c1sc2c(c1)nc([nH]c2=O)[C@@H]1CC2CCN1CC2
InChI InChI=1S/C17H19N5OS/c1-9-11(8-18-21-9)14-7-12-15(24-14)17(23)20-16(19-12)13-6-10-2-4-22(13)5-3-10/h7-8,10,13H,2-6H2,1H3,(H,18,21)(H,19,20,23)/t13-/m0/s1
InChI Key XGVXKJKTISMIOW-ZDUSSCGKSA-N
No information available.
Summary of Clinical Use Click here for help
TAK-931 has progressed to Phase 2 clinical evaluation in patients with advanced solid tumours. Click here to link to ClinicalTrials.gov's full list of TAK-931 trials.